Long-acting amylin analog
Cagrilintide
Human clinical trialsAn amylin analog being studied alone and in combination with semaglutide.
Evidence
Human clinical trials
Regulatory status
Investigational. Not FDA-approved.
Class
Long-acting amylin analog
What it is
Amylin is a hormone released alongside insulin that contributes to fullness. Cagrilintide is a long-acting version designed for once-weekly use.
What the research shows
- Studied in human trials, most notably combined with semaglutide (often called CagriSema).
- Late-stage trials are ongoing; it is not an approved medicine.
Read the published research on PubMed →
Researched for
Cagrilintide is not FDA-approved for the uses people commonly discuss. Its safety and effectiveness in people have not been established. Talk to a licensed provider before making any decision.
Educational content, not medical advice. This page does not recommend or dose any substance.
Related peptides
GLP-1 receptor agonist
Semaglutide
A GLP-1 receptor agonist and one of the most studied peptide medicines in the world.
FDA-approved drugDual GIP / GLP-1 receptor agonistTirzepatide
The first approved medicine that activates both the GIP and GLP-1 receptors.
FDA-approved drugTriple GIP / GLP-1 / glucagon receptor agonistRetatrutide
An investigational "triple agonist" currently in late-stage clinical trials.
Human clinical trials